Hangzhou Tigermed Consulting Co, a Chinese clinical research service provider, is considering a share sale in Hong Kong as soon as next year, according to people familiar with the matter.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
